Regeneron Pharmaceuticals EVP Commercial Executes $2.00M Rule 10b5-1 Stock Sale
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
📢 Insider Transaction Alert: REGENERON PHARMACEUTICALS, INC. ($REGN) Insider: McCourt Marion (EVP Commercial) Action: Open Market Sale (Rule 10b5-1 Plan) Shares Transacted: 2,346 shares Average Price: ~$853.56 Total Value: ~$2,002,458.09 Shares Held Following: 12,003 direct (plus 219 indirect via 401(k)) Significance: Low (Pre-scheduled Rule 10b5-1 Plan)
Comprehensive Analysis
Executive Summary
On September 2 and September 3, 2026, Marion McCourt, Executive Vice President, Commercial at Regeneron Pharmaceuticals, Inc. ($REGN), sold an aggregate of 2,346 shares of Common Stock for a total transaction value of approximately $2,002,458.09.
Transaction Breakdown
- September 2, 2026: Sold 1,215 shares at $850.00 per share ($1,032,750.00).
- September 3, 2026: Sold 1,131 shares at $857.39 per share ($969,708.09).
- Weighted Average Price: ~$853.56 per share.
Ownership Post-Transaction
- Direct Holdings: 12,003 shares of Common Stock.
- Indirect Holdings: 219 shares held via 401(k) Plan.
Key Context & Trading Significance
- 10b5-1 Trading Plan: These transactions were executed pursuant to a pre-established Rule 10b5-1(c) trading plan adopted on February 17, 2026.
- Significance Assessment: Low. Scheduled sales under Rule 10b5-1 plans are structured in advance and typically reflect routine portfolio management rather than a discretionary perspective on near-term corporate performance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.